Historically, lentiviral gene therapy has relied on ex vivo approaches, which require:
· Hematopoietic stem cell harvesting
· Complex cell processing and genetic modification
· Conditioning regimens
· Specialized manufacturing and clinical infrastructure
While clinically effective, these workflows are logistically intensive, limit scalability, and restrict patient access—particularly for infants and medically fragile patients.
In vivo lentiviral gene therapy introduces a fundamentally different paradigm.
Rather than manipulating cells outside the body, therapeutic gene delivery is performed directly within the patient, eliminating the need for cell extraction, ex vivo manipulation, and reinfusion.
A Unified In Vivo Gene Therapy Framework Across Multiple Genetic Diseases
HUMx Gateway™ is Humvira’s modular, scalable in vivo gene therapy framework designed to address multiple rare genetic disorders through a shared biological and delivery backbone.
Rather than developing each disease program in isolation, HUMx Gateway leverages a common in vivo lentiviral hematopoietic stem cell (HSC) gene therapy architecture, enabling efficient expansion across related indications while preserving a consistent mechanism of action.
Each disease program within the HUMx Gateway is defined by:
A shared in vivo HSC-lentiviral delivery paradigm
Disease-specific genetic payloads
A common stem-cell–level correction strategy
Long-term, self-renewing therapeutic potential from a single administration
This approach is designed to accelerate development across multiple rare diseases while maintaining scientific rigor, translational feasibility, and platform consistency.
Long Press to Scan QR Code
Scan QR Code
